 | Up a level |
Aoki, Shuichi; Inoue, Koetsu; Klein, Sebastian; Halvorsen, Stefan; Chen, Jiang; Matsui, Aya; Nikmaneshi, Mohammad R; Kitahara, Shuji; Hato, Tai; Chen, Xianfeng; Kawakubo, Kazumichi; Nia, Hadi T; Chen, Ivy; Schanne, Daniel H; Mamessier, Emilie; Shigeta, Kohei; Kikuchi, Hiroto; Ramjiawan, Rakesh R; Schmidt, Tyge Ce; Iwasaki, Masaaki; ... (2022). Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma. Gut, 71(1), pp. 185-193. BMJ Publishing Group 10.1136/gutjnl-2020-322493
Galle, Peter R; Kudo, Masatoshi; Llovet, Josep M; Finn, Richard S; Karwal, Mark; Pezet, Denis; Kim, Tae-You; Yang, Tsai-Sheng; Lonardi, Sara; Tomasek, Jiri; Phelip, Jean-Marc; Touchefeu, Yann; Koh, Su-Jin; Stirnimann, Guido; Liang, Kun; Ogburn, Kenyon D; Wang, Chunxiao; Abada, Paolo; Widau, Ryan C and Zhu, Andrew X (2021). Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. Liver international, 41(11), pp. 2759-2767. Wiley 10.1111/liv.14994
Kim, Richard D; Sarker, Debashis; Meyer, Tim; Yau, Thomas; Macarulla, Teresa; Park, Joong-Won; Choo, Su Pin; Hollebecque, Antoine; Sung, Max W; Lim, Ho-Yeong; Mazzaferro, Vincenzo; Trojan, Joerg; Zhu, Andrew X; Yoon, Jung-Hwan; Sharma, Sunil; Lin, Zhong-Zhe; Chan, Stephen L; Faivre, Sandrine; Feun, Lynn G; Yen, Chia-Jui; ... (2019). First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer discovery, 9(12), pp. 1696-1707. American Association for Cancer Research 10.1158/2159-8290.CD-19-0555
Zhu, Andrew X; Park, Joon Oh; Ryoo, Baek-Yeol; Yen, Chia-Jui; Poon, Ronnie; Pastorelli, Davide; Blanc, Jean-Frederic; Chung, Hyun Cheol; Baron, Ari D; Pfiffer, Tulio Eduardo Flesch; Okusaka, Takuji; Kubackova, Katerina; Trojan, Jorg; Sastre, Javier; Chau, Ian; Chang, Shao-Chun; Abada, Paolo B; Yang, Ling; Schwartz, Jonathan D; Kudo, Masatoshi; ... (2015). Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. The lancet oncology, 16(7), pp. 859-870. Elsevier 10.1016/S1470-2045(15)00050-9
Finn, Richard C; De Toni, Enrico N; Chung Cheung Yau, Thomas; Yen, Chia-Jui; Hsu, Chih-Hung; Chan, Stephen L; He, Aiwu Ruth; Galle, Peter; Trojan, Jörg; Stirnimann, Guido; Baron, Ari; Rivera, Mirelis Acosta; Goyal, Lipika; Wang, Chunxiao; Abada, Paolo; Widau, Ryan; Zhu, Andrew X (November 2020). Ramucirumab for patients with advanced HCC and elevated alpha-fetoprotein following non-sorafenib-based therapy: interim results from phase 3 REACH-2 expansion cohort. In: SOHC 2020 - Swiss Oncology & Hematology Congress - 3rd; Online Conference. November 18 - 21, 2020.
